Novartis trial setback seen widening early-2030s sales gap
Deutsche Bank’s Emmanuel Papadakis says Novartis’s latest clinical-trial setback raises questions about its acquisition track record and points to a sales hole to be plugged in the early 2030s.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.